Cytotoxic Chemotherapy for Pancreatic Cancer: Past, Present, and Future
作者： Robert A. Wolff
关键词: Internal medicine 、 Locally advanced disease 、 Oncology 、 Disease 、 Medicine 、 Cytotoxic chemotherapy 、 Clin oncol 、 Epidermal growth factor receptor 、 Pancreatic cancer
摘要: Progress in the treatment of pancreatic cancer has moved at a glacial pace. Continued investigation conventional cytotoxic agents is warranted and may result better palliation survival. Efforts to improve therapy should concentrate on further elucidation molecular mechanisms invasion, metastases, resistance. It expected that as for metastatic disease improves, patients with resectable locally advanced will also evolve.
springer.com
sci-hub.se 参考文章(72)
M.L. Rothenberg, M.J. Moore, M.C. Cripps, J.S. Andersen, R.K. Portenoy, H.A. Burriss, M.R. Green, P.G. Tarassoff, T.D. Brown, E.S. Casper, A.-M. Storniolo, D.D. Von Hoff, A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Annals of Oncology. ,vol. 7, pp. 347- 353 ,(1996) , 10.1093/OXFORDJOURNALS.ANNONC.A010600
M.L. Rothenberg, A. Sharma, G.R. Weiss, M.A. Villalona-Calero, J.R. Eckardt, C. Aylesworth, M.A. Kraynak, D.A. Rinaldi, G.I. Rodriguez, H.A. Burris, S.G. Eckhardt, C.D. Stephens, K. Forral, S.J. Nicol, D.D. Von Hoff, Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors Annals of Oncology. ,vol. 9, pp. 733- 738 ,(1998) , 10.1023/A:1008286908930
Stephen A. Cullinan, A Comparison of Three Chemotherapeutic Regimens in the Treatment of Advanced Pancreatic and Gastric Carcinoma JAMA. ,vol. 253, pp. 2061- 2067 ,(1985) , 10.1001/JAMA.1985.03350380077025
J A DeCaprio, R J Mayer, R Gonin, S G Arbuck, Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. Journal of Clinical Oncology. ,vol. 9, pp. 2128- 2133 ,(1991) , 10.1200/JCO.1991.9.12.2128
D.J.Th. Wagener, H.E.R. Verdonk, L.Y. Dirix, G. Catimel, P. Siegenthaler, M. Buitenhuis, A. Mathieu-Boué, J. Verweij, Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study Annals of Oncology. ,vol. 6, pp. 129- 132 ,(1995) , 10.1093/OXFORDJOURNALS.ANNONC.A059107
Marc A. Shampo, Robert A. Kyle, Godfrey Hounsfield--developer of computed tomographic scanning. Mayo Clinic proceedings. ,vol. 71, pp. 990- ,(1996) , 10.1016/S0025-6196(11)63774-9
Larry W. Hertel, William K Plunkett, Gerald B. Grindey, Volker Heinemann, Comparison of the Cellular Pharmacokinetics and Toxicity of 2′,2′-Difluorodeoxycytidine and 1-β-d-Arabinofuranosylcytosine Cancer Research. ,vol. 48, pp. 4024- 4031 ,(1988)
V. Heinemann, H. Wilke, H.-G. Mergenthaler, M. Clemens, H. König, H.J. Illiger, M. Arning, A. Schalhorn, K. Possinger, U. Fink, Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Annals of Oncology. ,vol. 11, pp. 1399- 1403 ,(2000) , 10.1023/A:1026595525977
N. Touroutoglou, D. Gravel, M.N. Raber, W. Plunkett, J.L. Abbruzzese, Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors Annals of Oncology. ,vol. 9, pp. 1003- 1008 ,(1998) , 10.1023/A:1008487932384
C H Spiridonidis, L R Laufman, J Jones, V A Rhodes, K Wallace, S Nicol, Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. Journal of Clinical Oncology. ,vol. 16, pp. 3866- 3873 ,(1998) , 10.1200/JCO.1998.16.12.3866